Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia
Fig 4
Epistaxis severity score variation during bevacizumab treatment.
Baseline score represents epistaxis severity 3 months before starting bevacizumab treatment. The dotted line is the fitted regression line (Linear mixed effects model).